{"url_path":"/sec/gwll/10-q/2026/cover-page","section_key":"cover-page","section_title":"Cover Page","topic":"sec","document":{"doc_type":"10-Q/A","doc_date":"2026-06-26","source_url":"https://www.sec.gov/Archives/edgar/data/1800373/0001477932-26-004052-index.html","accession_number":"0001477932-26-004052","cik":"0001800373","ticker":"GWLL","issuer_name":"GOLDENWELL BIOTECH, INC.","edgar_url":"https://www.sec.gov/Archives/edgar/data/1800373/0001477932-26-004052-index.html","primary_entity_key":"0001800373","primary_entity_name":"GOLDENWELL BIOTECH, INC."},"word_count":1126,"has_tables":true,"body_markdown":"gdwl_10qa.htm\n000180037310-Q/Atrue--12-31Q120250.00013000000009900000099000000falsefalsefalsefalse00018003732025-01-012025-03-310001800373gdwl:RestatedMember2025-03-310001800373gdwl:RestatedMember2025-01-012025-03-310001800373gdwl:AmountOfChangeMember2025-03-310001800373gdwl:AmountOfChangeMember2025-01-012025-03-310001800373srt:ScenarioPreviouslyReportedMember2025-03-310001800373srt:ScenarioPreviouslyReportedMember2025-01-012025-03-310001800373gdwl:FounderMember2019-12-310001800373gdwl:FounderMember2021-01-012021-01-110001800373gdwl:FounderMember2019-08-012019-08-2000018003732022-11-012022-11-0900018003732020-11-282020-12-0100018003732021-01-012021-01-1100018003732021-02-012021-02-2200018003732019-08-012019-08-2000018003732024-01-012024-12-310001800373gdwl:TreasurerMember2021-06-070001800373gdwl:AustralianTrefoilHeathTechnologyMember2021-06-052021-06-070001800373us-gaap:RetainedEarningsMember2025-03-310001800373gdwl:SubscriptionReceivableMember2025-03-310001800373us-gaap:AdditionalPaidInCapitalMember2025-03-310001800373gdwl:CommonStocksMember2025-03-310001800373us-gaap:RetainedEarningsMember2025-01-012025-03-310001800373us-gaap:RetainedEarningsMember2024-12-310001800373us-gaap:AdditionalPaidInCapitalMember2024-12-310001800373gdwl:CommonStocksMember2024-12-3100018003732024-03-310001800373us-gaap:RetainedEarningsMember2024-03-310001800373gdwl:SubscriptionReceivableMember2024-03-310001800373us-gaap:AdditionalPaidInCapitalMember2024-03-310001800373gdwl:CommonStocksMember2024-03-310001800373us-gaap:RetainedEarningsMember2024-01-012024-03-3100018003732023-12-310001800373us-gaap:RetainedEarningsMember2023-12-310001800373us-gaap:AdditionalPaidInCapitalMember2023-12-310001800373gdwl:CommonStocksMember2023-12-3100018003732024-01-012024-03-3100018003732024-12-3100018003732025-03-3100018003732025-05-21iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pure\n\n \n\n**UNITED STATES**\n\n**SECURITIES AND EXCHANGE COMMISSION**\n\n**Washington, D.C. 20549**\n\n \n\n**AMENDMENT NO. 1**\n\n**to**\n\n**FORM 10-Q**\n\n \n\n(MARK ONE)\n\n**☒**\n\n**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\nFor the quarterly period ended **March 31, 2025**\n\n \n\nOR\n\n \n\n**☐**\n\n**TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**\n\n \n\nFor the transition period from ____________ to ___________\n\n \n\nCommission File No. **000-56275**\n\n \n\n**GOLDENWELL BIOTECH, INC.**\n\n(Exact name of registrant as specified in its charter)\n\n \n\n**Nevada**\n\n**84-2896086**\n\n(State or other jurisdiction of incorporation or organization)\n\n(I.R.S. Employer Identification No.)\n\n \n\n**581 Boston Mills Road, Suite 300**\n\n**Hudson, Ohio 44087**\n\n (Address of principal executive offices, zip code)\n\n \n\n**(440) 666-7999**\n\n (Registrant’s telephone number, including area code)\n\n \n\n___________________________________________________________\n\n (Former name, former address and former fiscal year, if changed since last report)\n\n \n\nSecurities registered pursuant to Section 12(b) of the Act:\n\n \n\nTitle of each class\n\nTrading Symbol(s)\n\nName of each exchange on which registered\n\n \n\n \n\n \n\n \n\nIndicate by check mark whether the issuer (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒     No ☐\n\n \n\nIndicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files). Yes ☒     No ☐\n\n \n\nIndicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, or a smaller reporting company. See the definitions of “large accelerated filer,” “accelerated filer” and “smaller reporting company” in Rule 12b-2 of the Exchange Act. (check one):\n\n \n\nLarge accelerated filer\n\n☐\n\nAccelerated filer\n\n☐\n\nNon-accelerated filer\n\n☒\n\nSmaller reporting company\n\n☒\n\n \n\nEmerging growth company\n\n☒\n\n \n\nIf an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐\n\n \n\nIndicate by check mark whether the registrant is a shell company (as defined in Exchange Act Rule 12b-2 of the Exchange Act): Yes ☐    No ☒\n\n \n\n**APPLICABLE ONLY TO ISSUERS INVOLVED IN BANKRUPTCY PROCEEDINGS DURING THE PRECEDING FIVE YEARS:**\n\n \n\nIndicate by check mark whether the registrant has filed all documents and reports required to be filed by Sections 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court. Yes ☐    No ☐\n\n \n\n**APPLICABLE ONLY TO CORPORATE ISSUERS**\n\n \n\nAs of May 21, 2025, there were 99,000,000 shares of common stock, $0.001 par value per share, outstanding.\n\n \n\n \n\n \n\n \n\n**Explanatory Note**\n\n \n\nOn May 27, 2026, Goldenwell Biotech, Inc. (the “Company”), filed a Current Report on Form 8-K, disclosing, among other things, that the financial statements disclosed in the Company’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025 (the “March 31, 2025 Form 10-Q”), filed with the Securities and Exchange Commission (the “SEC”) on May 27, 2025, could no longer be relied upon. This Amendment No. 1 to Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, fully restates the Company’s financial statements for the fiscal quarter ended March 31, 2025, and its related notes to financial statements and related disclosures in **Item 2 (Management’s Discussion and Analysis of Financial Condition and Results of Operations).**\n\n \n\n \n\n2\n\n \n\n \n\n**GOLDENWELL BIOTECH, INC.**\n\n**QUARTERLY REPORT ON FORM 10-Q**\n\n**FOR THE PERIOD ENDED MARCH 31, 2025**\n\n \n\n**INDEX**\n\n \n\n**Index**\n\n**Page**\n\n**PART I. FINANCIAL INFORMATION**\n\n[Item 1.](#P1I1)\n\n[Financial Statements.](#P1I1)\n\n5\n\n[Balance Sheet as of March 31, 2025 (unaudited) and December 31, 2024.](#BS)\n\n5\n\n[Statement of Operations for the Three Months ended March 31, 2025 and 2024 (unaudited)](#SO)\n\n6\n\n \n\n \n\n \n\n \n\n \n\n \n\n[Statements of Changes Stockholders’ Equity for the Three Months ended March 31, 2025 and the year ended December 31, 2024 (unaudited).](#SE)\n\n7\n\n \n\n \n\n \n\n \n\n \n\n \n\n \n\n[Statement of Cash Flows for the Three Months ended March 31, 2025 and 2024 (unaudited).](#CF)\n\n \n\n \n\n8\n\n \n\n[Notes to Condensed Financial Statements (unaudited).](#NTS)\n\n9\n\n[Item 2.](#P1I2)\n\n[Management’s Discussion and Analysis of Financial Condition and Results of Operations.](#P1I2)\n\n13\n\n[Item 3.](#P1I3)\n\n[Quantitative and Qualitative Disclosures About Market Risk.](#P1I3)\n\n15\n\n[Item 4.](#P1I4)\n\n[Controls and Procedures.](#P1I4)\n\n16\n\n**PART II. OTHER INFORMATION**\n\n[Item 1.](#P2I1)\n\n[Legal Proceedings.](#P2I1)\n\n17\n\n[Item 1A.](#P2I1A)\n\n[Risk Factors.](#P2I1A)\n\n17\n\n[Item 2.](#P2I2)\n\n[Unregistered Sales of Equity Securities and Use of Proceeds.](#P2I2)\n\n17\n\n[Item 3.](#P2I3)\n\n[Defaults Upon Senior Securities.](#P2I3)\n\n17\n\n[Item 4.](#P2I4)\n\n[Mine Safety Disclosures.](#P2I4)\n\n17\n\n[Item 5.](#P2I5)\n\n[Other Information.](#P2I5)\n\n17\n\n[Item 6.](#P2I6)\n\n[Exhibits.](#P2I6)\n\n17\n\n**Signatures**\n\n18\n\n \n\n \n\n3\n\n*Table of Contents*\n\n \n\n**CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS**\n\n \n\nThis Amendment No. 1 to Quarterly Report on Form 10-Q of Goldenwell Biotech, Inc., a Nevada corporation (the “Company”), contains “forward-looking statements,” as defined in the United States Private Securities Litigation Reform Act of 1995. In some cases, you can identify forward-looking statements by terminology such as “may”, “will”, “should”, “could”, “expects”, “plans”, “intends”, “anticipates”, “believes”, “estimates”, “predicts”, “potential” or “continue” or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. The economic environment within which we operate could materially affect our actual results. Additional factors that could materially affect these forward-looking statements and/or predictions include, among other things to product demand, market and customer acceptance, competition, pricing, climate change, pandemics, political changes, and development difficulties, as well as general industry and market conditions and growth rates and general economic conditions; and other factors discussed in the Company’s filings with the Securities and Exchange Commission (“SEC”).\n\n \n\nOur management has included projections and estimates in this Form 10-Q, which are based primarily on management’s experience in the industry, assessments of our results of operations, discussions and negotiations with third parties and a review of information filed by our competitors with the SEC or otherwise publicly available. We caution readers not to place undue reliance on any such forward-looking statements, which speak only as of the date made. We disclaim any obligation subsequently to revise any forward-looking statements to reflect events or circumstances after the date of such statements or to reflect the occurrence of anticipated or unanticipated events. \n\n \n\n \n\n4\n\n*Table of Contents*\n\n \n\n**PART I. FINANCIAL INFORMATION**"}